What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the naturally occurring hormone GLP-1 (glucagon-like peptide-1). Developed by Novo Nordisk, it works by binding to GLP-1 receptors in the body, which triggers several effects:
- Slows gastric emptying, so food moves through your stomach more slowly and you feel full longer
- Reduces appetite by acting on hunger centers in the brain
- Increases insulin secretion and reduces glucagon release, improving blood sugar control
The result is that patients eat less, feel satisfied sooner, and experience meaningful weight loss alongside improved metabolic health.
FDA-Approved Forms
| Brand Name | Indication | Route | FDA Approved |
|---|---|---|---|
| Ozempic | Type 2 Diabetes | Weekly injection (pen) | Dec 2017 |
| Wegovy | Chronic weight management | Weekly injection (pen) | Jun 2021 |
| Rybelsus | Type 2 Diabetes | Daily oral tablet | Sep 2019 |
Ozempic and Wegovy contain the same active ingredient but are approved for different conditions and use different dosing schedules. Rybelsus is the oral formulation, currently approved only for type 2 diabetes.
Clinical Results
Weight Loss (STEP Trials)
The landmark STEP clinical trial program demonstrated that semaglutide 2.4 mg (Wegovy) produces approximately 15-17% total body weight loss over 68 weeks. For a 250-pound patient, that translates to roughly 38-43 pounds.
Cardiovascular Benefits (SELECT Trial)
The SELECT trial showed that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with obesity and established cardiovascular disease — even in those without diabetes. This was a landmark finding that demonstrated benefits beyond weight loss.
Dosing Schedule
Wegovy (Weight Management)
Wegovy uses a gradual dose escalation to minimize side effects:
| Week | Dose | Frequency |
|---|---|---|
| Weeks 1-4 | 0.25 mg | Once weekly |
| Weeks 5-8 | 0.5 mg | Once weekly |
| Weeks 9-12 | 1.0 mg | Once weekly |
| Weeks 13-16 | 1.7 mg | Once weekly |
| Week 17+ | 2.4 mg (maintenance) | Once weekly |
Ozempic (Type 2 Diabetes)
Ozempic follows a similar escalation but targets different maintenance doses (0.5 mg, 1.0 mg, or 2.0 mg) based on glycemic response.
Common Side Effects
Most side effects are gastrointestinal and tend to improve within the first few weeks as your body adjusts:
- Nausea (most common, especially during dose increases)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Serious but Rare Side Effects
- Pancreatitis — seek immediate medical attention for severe, persistent abdominal pain
- Gallbladder problems — rapid weight loss can increase gallstone risk
- Thyroid C-cell tumors — observed in animal studies; clinical relevance in humans is uncertain but the warning is on the label
Who Should NOT Take Semaglutide
- Personal or family history of medullary thyroid carcinoma (MTC)
- Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy or planning to become pregnant — discontinue at least 2 months before planned conception
- Known hypersensitivity to semaglutide or any product components
Insurance and Cost
List Pricing
- Wegovy: approximately $1,300-$1,600 per month at retail
- Ozempic: similar range, though insurance coverage for diabetes is often better
Savings Programs
Novo Nordisk offers savings cards and patient assistance programs. Eligibility varies by insurance status and income.
Price Reductions
Novo Nordisk has announced list price reductions of approximately 35-50% for Wegovy, effective January 2027. This is expected to significantly improve access for patients.
How Valitide Helps
Valitide's clinical team can evaluate whether semaglutide is appropriate for you, verify your insurance coverage, help you enroll in available savings programs, and provide ongoing clinical support throughout your treatment. If semaglutide isn't covered by your plan, we help identify the most cost-effective alternative pathway.